On May 27, 2022 NEX-I reported that the company selected NXI-101, a new antibody treatment for non-small cell lung cancer that targets immunotherapy-refractory factors (Press release, NEX-I, MAY 27, 2022, View Source;mode=VIEW&num=15&category=&findType=&findWord=&sort1=&sort2=&page=3 [SID1234643432]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CEO Kyung-wan Yoon"NXI-101Not only does it improve the survival rate of patients who do not respond to existing immunotherapy treatments,,As an anticancer drug that guarantees the patient’s quality of life after treatment, it will bring a new paradigm to the cancer immunotherapy market."said.

The national new drug development project is a domestic pharmaceutical·To strengthen the global competitiveness of the bio industry and secure pharmaceutical sovereignty, which is an essential condition for public health, pharmaceutical companies and academia·kite·Based on bottle open innovation strategy,A pan-ministerial country that supports all stages of new drug developmentR&DStarting this year as a business10years2article2000Investing billions of won.

With the selection of this project, NexI plans to2yearsNXI-101You will receive support for the research costs necessary to derive the lead material.. NXI-101It targets immune evasion factors specifically secreted by cancer cells.First-in-classIt is a new antibody drug..Immune evasion factors are the cause of refractoriness to anticancer immunotherapy.,Controlling this can significantly improve the efficacy of anticancer immunotherapy..

The company said"New drugs under development are derived based on data from a number of immunotherapy-refractory animal models established in-house and from patients who are actually refractory to anti-cancer immunotherapy, so effective clinical efficacy can be expected."He said.

Meanwhile,Nexi this year4It is a new bio venture company established in February..Chief Scientific Officer of Genome & Company(CSO)·CEO Kyung-wan Yoon, who served as vice president,20Through more than a year of research on incurable cancer diseases, many anticancer drugs have been developed.·Professor Kim Tae-woo of Korea University College of Medicine, who has research achievements in immunotherapy, is the Chief Technology Officer.(CTO)I am in charge of.

On May 27, 2022 Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, reported that it will be presenting a poster at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, being held at McCormick Place in Chicago and virtually from June 3-7, 2022 (Press release, Bolt Biotherapeutics, MAY 27, 2022, View Source [SID1234618688]). The poster is titled "Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune-stimulating antibody conjugates (ISACs)."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The data being presented at ASCO (Free ASCO Whitepaper) demonstrate that myeloid cells are consistently present in solid tumors. We believe this represents an attractive cellular target to address cancer more broadly. Myeloid cells are key cell types that serve as immunologic sentinels within the tumor microenvironment and can directly kill tumor cells or activate long-lasting cytotoxic T cells," said Edith A. Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics. "Myeloid-targeted therapies, as single-agents or in combination with approved therapies, have the potential to benefit patients who may or may not have previously benefited from T cell-targeted approaches."

Bolt Biotherapeutics is currently developing a pipeline of myeloid-targeting therapies, including immune-stimulating antibody conjugates (ISACs) and BDC-3042 (a Dectin-2 agonistic antibody), designed to kill tumors through activation of myeloid cells and subsequent recruitment of T cells. Bolt researchers characterized the myeloid immune landscape of tumor microenvironments from five solid tumor types. The data demonstrate that myeloid cells are present in all tested tumor microenvironments, including those with low T cell infiltration. These findings support the potential for myeloid-directed therapies to activate the innate immune system as a bridge to adaptive immunity, including patient populations who have demonstrated resistance to T cell-mediated immune checkpoint blockade. The data also validate the tumor cell expression of tumor antigens HER2, CEA, and PD-L1, all of which are targets of Boltbody ISAC candidates.

The ASCO (Free ASCO Whitepaper) abstract and poster presentation can be found on the Bolt website under Events & Presentations. Details regarding the presentation are as follows.

Title: Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune stimulating antibody conjugates (ISACs)
Presented by: Jason Ptacek, Ph.D.
Poster Session: Developmental Therapeutics – Immunotherapy
Time: Sunday, June 5, 8:00 a.m. – 11:00 a.m. CDT
Abstract Number: 2557
Poster Number: 212

On May 27, 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, reported new interim data from Part A of the Phase II TACTI-002 trial in 1st line NSCLC has been published today in an abstract at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper)’s (ASCO) (Free ASCO Whitepaper) 2022 Annual Meeting (Press release, Immutep, MAY 27, 2022, View Source [SID1234615248]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data from the trial will be presented in an Oral Presentation on 3 June 2022. Importantly, while the abstract contains data from the first 75 patients with a data cut off of January 2022, the Oral Presentation will present data from all 114 patients with a more recent data cut off and will be the subject of a further announcement from the Company.

Immutep also announces the publication of an abstract for the design of the ongoing Phase IIb TACTI-003 trial that will be presented as a Trial-in-Progress Poster Presentation at ASCO (Free ASCO Whitepaper) 2022.

The respective abstracts are available via the links below and www.immutep.com. Similarly, the presentations will be available at the times indicated below on ASCO (Free ASCO Whitepaper).org and subsequently made available on Immutep’s website.

TACTI-002 Abstract
Title: A Phase II study (TACTI-002) in 1st line metastatic non-small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: updated results from a PD-L1 unselected population
Abstract link: View Source 2022/ASCO 2022_TACTI-002 part A_Abstract_Final.pdf
Oral presentation date: Friday 3 June 2022 at 1:00pm, US Central Daylight Time (CDT)

TACTI-003 Abstract
Title: TACTI-003: A randomized Phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous-cell carcinoma
Abstract link: View Source 2022/ASCO 2022_TACTI-003_TIP_Abstract_Final.pdf
Poster date: Monday 6 June 2022 at 1:15pm US CDT

On May 27, 2022 Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, reported financial results for the first quarter ended March 31, 2022 (Press release, Allarity Therapeutics, MAY 27, 2022, View Source [SID1234615219]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

F irst Quarter Financial Results

Balance Sheet: As of March 31, 2022, Allarity’s cash was $14.5 million, as compared to $19.6 million as of December 31, 2021.

R&D Expenses: Research and Development (R&D) expenses were $1.3 million for the three months ended March 31, 2022, compared to $1.3 million for the quarter ended March 31, 2021.

Impairment of Intangible Assets : Impairment of Intangible Assets was $14.0 million for the three months ended March 31, 2022, compared to nil for the quarter ended March 31, 2021.

G&A Expenses: General and Administrative (G&A) expenses were $3.0 million for the three months ended March 31, 2022, as compared to $1.2 million for the three months ended March 31, 2021.

Net Loss: Net loss was $3.1 million for the three months ended March 31, 2022, compared to $3.1 million for the comparable period in 2021.

On May 27, 2022 OriCell Therapeutics Co., Ltd (OriCell), a leading innovative biopharmaceutical company pioneering novel oncology cell therapies for the unmet medical needs in in hematology and oncology, reported that an abstract detailing data from a Phase I study(POLARIS) evaluating OriCAR-017 in patients with Relapsed/Refractory Multiple Myeloma will be presented an oral session at the upcoming 2022 ASCO (Free ASCO Whitepaper) Annual Meeting on Sunday, June 5th (Press release, OriCell Therapeutics, MAY 27, 2022, View Source;oricell-therapeutics-announces-oral-presentation-at-2022-asco-annual-meeting-detailing-results-from-phase-i-polaris-study-of-oricar-017-301556668.html [SID1234615218]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About POLARIS Study

This is a Phase I first-in-human study of OriCAR-017 in patients with Relapsed/Refractory Multiple Myeloma (NCT05016778).

POLARIS study enrolled adults with measurable MM, R/R or intolerant to established MM therapies, prior BCMA-targeted therapy allowed. OriCAR-017 was administered by a single infusion at 3 dose cohorts to 9 patients. In all patients, majority of AEs were transient, manageable, and reversible. CRS only in Grade 1or2. No DLT, Neurotoxicities been observed. No death due to AE. Responses were durable and deepened overtime with 100% ORR and 100% MRD negative rate, including BCMA CAR-T relapsed patients, all patients are progression free and followed without additional therapy at the cutoff date. Updated data will be oral presented at the upcoming 2022 ASCO (Free ASCO Whitepaper) Annual Meeting, in McCormick Place, Chicago, IL on June 3-7, 2022.

Details for the abstract as below:

Abstract ID: 8004
Abstract Title: Phase I open-label single arm study of GPRC5D CAR T-cells (OriCAR-017) in patients with relapsed/refractory multiple myeloma (POLARIS)
Session Type/Title: Oral Abstract Session/ Hematologic Malignancies—Plasma Cell Dyscrasia
Session Date and Time: Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT
Link：View Source

About OriCAR Technology Platform

An autologous GPRC5D-directed CAR T cell with a memory and anti-exhaustion T cells phenotype on the basis of the standard second generation CAR T cell, which improves the expansion and durability of CAR-T post-transfusion.